oracine has been researched along with camptothecin in 2 studies
Studies (oracine) | Trials (oracine) | Recent Studies (post-2010) (oracine) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
---|---|---|---|---|---|
33 | 0 | 4 | 13,002 | 2,229 | 5,391 |
Protein | Taxonomy | oracine (IC50) | camptothecin (IC50) |
---|---|---|---|
Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Antony, S; Cushman, M; Fort, BC; Kohlhagen, G; Meckley, MR; Morrell, A; Nagarajan, M; Pommier, Y | 1 |
Antony, S; Cushman, M; Kohlhagen, G; Morrell, A; Pommier, Y | 1 |
2 other study(ies) available for oracine and camptothecin
Article | Year |
---|---|
Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Electrophoresis, Polyacrylamide Gel; Humans; Indenes; Isoquinolines; Models, Molecular; Topoisomerase I Inhibitors | 2004 |
Synthesis of benz[d]indeno[1,2-b]pyran-5,11-diones: versatile intermediates for the design and synthesis of topoisomerase I inhibitors.
Topics: Drug Design; Enzyme Inhibitors; Pyrans; Topoisomerase I Inhibitors | 2006 |